P – AML patients with poor or intermediate prognosis [≥60 years, with white blood cell count at diagnosis ≥30,000 or <50,000/mm3 complex karyotypes (≥3 chromosomal abnormalities), secondary AML, changes in chromosome 3 or 7) undergoing consolidation therapy.

I – Use of cytarabine (400 mg/m2/day, 2 g/m2/day, 3 g/m2/day, 4 g/m2/day, or 6 g/m2/day)

C –

O – Complete remission rate, overall survival, and disease-free survival